Bayesian meta‐analytical methods to incorporate multiple surrogate endpoints in drug development process.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Works matching IS 02776715 AND DT 2022 AND VI 41 AND IP 30
Results: 7
1
2
Overall assessment for selected markers from high‐throughput data.
- Published in:
- Statistics in Medicine, 2022, v. 41, n. 30, p. 5830, doi. 10.1002/sim.9596
- By:
- Publication type:
- Article
3
Sample size determination for the association between longitudinal and time‐to‐event outcomes using the joint modeling time‐dependent slopes parameterization.
- Published in:
- Statistics in Medicine, 2022, v. 41, n. 30, p. 5810, doi. 10.1002/sim.9595
- By:
- Publication type:
- Article
4
Practical implementation of the partial ordering continual reassessment method in a Phase I combination‐schedule dose‐finding trial.
- Published in:
- Statistics in Medicine, 2022, v. 41, n. 30, p. 5789, doi. 10.1002/sim.9594
- By:
- Publication type:
- Article
5
Dose finding studies for therapies with late‐onset toxicities: A comparison study of designs.
- Published in:
- Statistics in Medicine, 2022, v. 41, n. 30, p. 5767, doi. 10.1002/sim.9593
- By:
- Publication type:
- Article
6
Review and evaluation of imputation methods for multivariate longitudinal data with mixed‐type incomplete variables.
- Published in:
- 2022
- By:
- Publication type:
- Literature Review
7
Issue Information.
- Published in:
- Statistics in Medicine, 2022, v. 41, n. 30, p. 1, doi. 10.1002/sim.9072
- Publication type:
- Article